Literature DB >> 11305976

Therapeutic options in patients with reduced ejection fraction and nonsustained ventricular tachycardia.

E C Palma1.   

Abstract

The patient with a reduced ejection fraction and nonsustained ventricular tachycardia represents a common management problem for the physician. This article reviews the supporting evidence for the therapeutic options available for these patients according to the etiology of the reduced ejection fraction. In postinfarction patients, electrophysiology-guided implantable cardioverter defibrillator therapy improves survival more than antiarrhythmic therapy. In patients with nonischemic cardiomyopathy, the best therapy is yet undetermined. Ongoing clinical trials will hopefully direct future therapy.

Entities:  

Mesh：

Year:  2001        PMID： 11305976     DOI： 10.1007/s11886-001-0026-9

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN： 1523-3782            Impact factor:   2.931


  41 in total

1.  A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias.

Authors: 
Journal:  N Engl J Med       Date:  1997-11-27       Impact factor: 91.245

2.  Nonsustained ventricular tachycardia in severe heart failure. Independent marker of increased mortality due to sudden death. GESICA-GEMA Investigators.

Authors:  H C Doval; D R Nul; H O Grancelli; S D Varini; S Soifer; G Corrado; S Dubner; O Scapin; S V Perrone
Journal:  Circulation       Date:  1996-12-15       Impact factor: 29.690

3.  Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators.

Authors:  J A Cairns; S J Connolly; R Roberts; M Gent
Journal:  Lancet       Date:  1997-03-08       Impact factor: 79.321

4.  Controlled trial of sotalol for one year after myocardial infarction.

Authors:  D G Julian; R J Prescott; F S Jackson; P Szekely
Journal:  Lancet       Date:  1982-05-22       Impact factor: 79.321

5.  Predictors of total mortality and sudden death in mild to moderate heart failure. Captopril-Digoxin Study Group.

Authors:  A Gradman; P Deedwania; R Cody; B Massie; M Packer; B Pitt; S Goldstein
Journal:  J Am Coll Cardiol       Date:  1989-09       Impact factor: 24.094

6.  Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA)

Authors:  H C Doval; D R Nul; H O Grancelli; S V Perrone; G R Bortman; R Curiel
Journal:  Lancet       Date:  1994-08-20       Impact factor: 79.321

7.  Prevalence and significance of nonsustained ventricular tachycardia in patients with premature ventricular contractions and heart failure treated with vasodilator therapy. Department of Veterans Affairs CHF STAT Investigators.

Authors:  S N Singh; S G Fisher; P E Carson; R D Fletcher
Journal:  J Am Coll Cardiol       Date:  1998-10       Impact factor: 24.094

8.  Determinants of prognosis in idiopathic dilated cardiomyopathy as determined by programmed electrical stimulation.

Authors:  T Meinertz; N Treese; W Kasper; A Geibel; T Hofmann; M Zehender; D Bohn; T Pop; H Just
Journal:  Am J Cardiol       Date:  1985-08-01       Impact factor: 2.778

9.  Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure.

Authors:  S N Singh; R D Fletcher; S G Fisher; B N Singh; H D Lewis; P C Deedwania; B M Massie; C Colling; D Lazzeri
Journal:  N Engl J Med       Date:  1995-07-13       Impact factor: 91.245

10.  Significance of ventricular tachycardia in idiopathic dilated cardiomyopathy: observations in 35 patients.

Authors:  S K Huang; J V Messer; P Denes
Journal:  Am J Cardiol       Date:  1983-02       Impact factor: 2.778
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.